Esco Lifesciences raises $200m in Vivo Capital, Novo Holdings-led round

Esco Lifesciences raises $200m in Vivo Capital, Novo Holdings-led round

Photo by Louis Reed on Unsplash

Singapore-based Esco Lifesciences, which provides products and services for the life sciences and healthcare industries, has announced the closure of an oversubscribed $200 million Series A and crossover round led by Vivo Capital and Novo Holdings.  

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter